Tan, Zibin
Yang, Weizhun http://orcid.org/0000-0001-5522-4026
O’Brien, Nicholas A. http://orcid.org/0000-0002-7682-3420
Pan, Xingling
Ramadan, Sherif
Marsh, Terence
Hammer, Neal http://orcid.org/0000-0001-6148-7850
Cywes-Bentley, Colette
Vinacur, Mariana
Pier, Gerald B. http://orcid.org/0000-0002-9112-2331
Gildersleeve, Jeffrey C. http://orcid.org/0000-0002-3744-6423
Huang, Xuefei
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (R01AI146210)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (Intramural Research)
Michigan State University
Article History
Received: 19 October 2023
Accepted: 3 April 2024
First Online: 24 April 2024
Competing interests
: X.H. is the founder of Iaso Therapeutics Inc., which is dedicated to the development of next generation of vaccines. G.B. P. has a financial interest in Alopexx, Inc. a company developing broad-spectrum immune therapeutics, which target PNAG for the prevention, treatment, and mitigation of bacterial, fungal, and parasitic infections. G.B.P.’s interests were reviewed and are managed by Brigham and Women’s Hospital and Mass General Brigham in accordance with their conflict-of-interest policies. All other authors declare no competing interests.